Suppr超能文献

凝血因子 V(A2440G) 通过 TFPIα 导致东德克萨斯出血性疾病。

Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα.

机构信息

Department of Internal Medicine, Division of Medical Genetics, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.

出版信息

J Clin Invest. 2013 Sep;123(9):3777-87. doi: 10.1172/JCI69091. Epub 2013 Aug 27.

Abstract

The autosomal dominantly inherited east Texas bleeding disorder is linked to an A2440G variant in exon 13 of the F5 gene. Affected individuals have normal levels of coagulation factor V (FV) activity, but demonstrate inhibition of global coagulation tests. We demonstrated that the A2440G mutation causes upregulation of an alternatively spliced F5 transcript that results in an in-frame deletion of 702 amino acids of the large activation fragment, the B domain. The approximately 250-kDa FV isoform (FV-short), which can be fully activated by thrombin, is present in all A2440G carriers' plasma (n = 16). FV-short inhibits coagulation through an indirect mechanism by forming a complex with tissue factor pathway inhibitor-α (TFPIα), resulting in an approximately 10-fold increase in plasma TFPIα, suggesting that the TFPIα:FV-short complexes are retained in circulation. The TFPIα:FV-short complexes efficiently inhibit thrombin generation of both intrinsic and extrinsic coagulation pathways. These data demonstrate that the east Texas bleeding disorder-associated F5(A2440G) leads to the formation of the TFPIα:FV-short complex, which inhibits activation and propagation of coagulation.

摘要

常染色体显性遗传的德克萨斯州东部出血性疾病与 F5 基因第 13 外显子的 A2440G 变体相关。受影响的个体具有正常水平的凝血因子 V(FV)活性,但表现出对整体凝血测试的抑制。我们证明,A2440G 突变导致异常剪接的 F5 转录本上调,从而导致大激活片段(B 域)的 702 个氨基酸缺失。大约 250 kDa 的 FV 同种型(FV-short)可被凝血酶完全激活,存在于所有 A2440G 携带者的血浆中(n = 16)。FV-short 通过与组织因子途径抑制剂-α(TFPIα)形成复合物,通过间接机制抑制凝血,导致血浆 TFPIα 增加约 10 倍,这表明 TFPIα:FV-short 复合物保留在循环中。TFPIα:FV-short 复合物可有效抑制内源性和外源性凝血途径的凝血酶生成。这些数据表明,与德克萨斯州东部出血性疾病相关的 F5(A2440G)导致 TFPIα:FV-short 复合物的形成,从而抑制凝血的激活和传播。

相似文献

引用本文的文献

6
The Prothrombin-Prothrombinase Interaction.凝血酶原-凝血酶酶促复合物的相互作用。
Subcell Biochem. 2024;104:409-423. doi: 10.1007/978-3-031-58843-3_15.
7
Factor V variants in bleeding and thrombosis.出血和血栓形成中的凝血因子V变体
Res Pract Thromb Haemost. 2024 Jan 26;8(1):102330. doi: 10.1016/j.rpth.2024.102330. eCollection 2024 Jan.
10
Structural architecture of the acidic region of the B domain of coagulation factor V.凝血因子 V B 结构域酸性区的结构架构。
J Thromb Haemost. 2024 Mar;22(3):709-714. doi: 10.1016/j.jtha.2023.11.003. Epub 2023 Nov 23.

本文引用的文献

3
Hemostatic properties of a TFPI antibody.组织因子途径抑制物抗体的止血特性。
Thromb Res. 2012 May;129 Suppl 2:S44-5. doi: 10.1016/j.thromres.2012.02.030. Epub 2012 Mar 8.
4
Tissue factor pathway inhibitor: structure-function.组织因子途径抑制剂:结构-功能。
Front Biosci (Landmark Ed). 2012 Jan 1;17(1):262-80. doi: 10.2741/3926.
6
The molecular basis of factor V and VIII procofactor activation.因子 V 和 VIII 辅因子激活的分子基础。
J Thromb Haemost. 2009 Dec;7(12):1951-61. doi: 10.1111/j.1538-7836.2009.03622.x. Epub 2009 Sep 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验